Holistic artificial intelligence-driven predictor in HER2-positive (HER2+) early breast cancer (BC) treated with neoadjuvant lapatinib and trastuzumab without chemotherapy: A correlative analysis from SOLTI-1114 PAMELA
Por:
Batistella, E, Pare, L, Sahasrabudhe, M, Pascual, T, Vakalopoulou, M, Villagrasa, P, Deutsch, E, Chic, N, Villacampa, G, Nuciforo, P, Cortes, J, Llombart-Cussac, A, Paragios, N and Prat, A
Publicada:
1 feb 2021
Resumen:
Filiaciones:
Batistella, E:
Univ Paris Saclay, CentraleSupelec, Paris, France
Pare, L:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Sahasrabudhe, M:
Univ Paris Saclay, CentraleSupelec, Paris, France
Pascual, T:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Vakalopoulou, M:
Univ Paris Saclay, CentraleSupelec, Paris, France
Villagrasa, P:
SOLTI Breast Canc Res Grp, Barcelona, Spain
Deutsch, E:
Univ Paris Saclay, Inst Gustave Roussy, Paris, France
Chic, N:
Hosp Clin Barcelona, Barcelona, Spain
Villacampa, G:
Vall dHebron Inst Oncol, Oncol Data Sci Grp, Barcelona, Spain
Nuciforo, P:
Vall dHebron Univ Hosp, Barcelona, Spain
Cortes, J:
Quiron Grp, IOB Inst Oncol, Barcelona, Spain
:
Hosp Arnau Vilanova, Dept Med Oncol, Valencia, Spain
Paragios, N:
TheraPanacea, Paris, France
Prat, A:
Hosp Clin Barcelona, Barcelona, Spain
|